Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cutan Pathol. 2010 Mar;37(3):316-22. doi: 10.1111/j.1600-0560.2009.01428.x. Epub 2009 Sep 24.

IMP-3 expression in melanocytic lesions.

Author information

  • 1Department of Pathology, Dermatopathology Division, University of Michigan, M3260, Medical Sciences 1, 1301 Catherine Street, Ann Arbor, MI 48109-0602, USA.

Abstract

BACKGROUND:

Insulin-like growth factor-II mRNA-binding protein 3 (IMP-3 ), a member of the insulin-like growth factor mRNA-binding protein family, is expressed in several human malignancies, including melanomas. However, the expression of IMP-3 has not been explored in melanoma in situ, various histologic subtypes of invasive melanomas and atypical Spitz tumors.

METHODS:

IMP-3 immunostain was performed in 157 melanocytic lesions.

RESULTS:

Nearly all benign (8/8), dysplastic (8/8) and Spitz nevi (8/9) were negative for IMP-3. Focal IMP-3 positivity was observed in 5/12 melanoma in situ and 4/15 superficial melanomas (Breslow depth <or=1 mm). Half (10/20) of deep melanomas (Breslow depth >1 mm) and 25/52 metastatic melanomas demonstrated strong IMP-3 staining. IMP-3 expression differs significantly between non-desmoplastic melanomas (superficial and deep) and benign or dysplastic or Spitz nevi (p = 0.0427, respectively). Four of 23 desmoplastic melanomas expressed IMP-3 , which was significantly different from deep melanomas (p = 0.0109). IMP-3 stained 7 of 10 atypical Spitz tumors. The difference between atypical Spitz tumors and Spitz nevi was statistically significant (p = 0.0256).

CONCLUSION:

A malignant circumstance, such as non-desmoplastic melanoma or atypical Spitz tumor, can be inferred when IMP-3 is expressed, suggesting potential diagnostic value of IMP-3 in melanocytic lesions.

PMID:
19788446
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk